Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
not from me
(I gave up trying to have anything close to a "debate" on iHub years ago. There's some great info in these boards, but it often comes with ego.)
There are definitely some reasons the CEO would want to do an investor roadshow .. notably to attract investors which will drive up the share price and give the company leverage in discussions they may have around partnerships, acquisitions, etc. The CEO is the single largest holder I believe, so he also stands to gain the most in the event he wants to shed a few shares and benefit from the fruits of his efforts. These conferences are also great networking events and allow companies to get exposure to their industry peers, companies offering ancillary services, etc. All just IMO.
all Dec 31 inventory already sold? And cost already at $1/g .. damn.
Good article about VFF on SA: https://seekingalpha.com/article/4246534-village-farms-hottest-cannabis-stock-right-now
Without a doubt, yeast based production will be the future, but that's still many years out. Cannabis has so many different compounds that have unique benefits, that more studies need to be done before the yeast approach makes sense (since you grow only one compound at a time).
It's still "natural" in the sense that the compounds are identical to those that are extracted, the advantages of growing them in a vat is the purity and scale (and lower cost). But it's not super easy to do at scale. EVOLVA, a Swiss company, is doing this with increasing success for Stevia, nootkatone, and reservatrol. Once the cannabinoids market starts to mature I have no doubt this approach will take market share, but IMO that's 6+ years out. Until then VFF will do stunningly.
With the clear strength and pedigree of their growers, management, and business strategy, if on top of this they release great numbers from cultivation and sales, and can prove their yield and their costs were as they'd always claimed, this would cement the market's confidence and send the share price much higher IMO.
Village Fields! Nice.
I don't smoke but when I saw how cool the DabTabs were, I almost wish I did. High-tech weed. Exciting times.
They sold 200 million shares at 3.5p each Read the PR. Those shares hit the market yesterday I believe. The O/S was diluted enormously.
MTPH in London is priced in GBX which is pence (1/100 of a pound). MTP on Nasdaq is an ADR, representing two ordinary shares, so it should be double the London price (adjusted for FX conversion).
And a prior poster was right.. the shares just bought by China Medical Systems were bought at 3.85 pence, or $0.10 per ADR. Today's Nasdaq action pushed ADR's to over $0.50, which is a HUGE premium over the last London price.
Regardless of this crazy action today, the company remains hugely undervalued. They now have cash in the bank, a licensor in two markets they weren't likely to focus on anyway, and some runway to focus on moving things forward in the US and Europe.
Wow today but not wow looking back 6-18 months I wish I'd set a stop loss on this one .. I took a position a couple of years ago and watched it drift down. Huge potential, esp from here, but it can be a long slog.
Report: Resonant’s Strategy to Tackle 5G
https://tailwindsresearch.com/2019/02/resonants-strategy-to-tackle-5g/
(contents were forwarded to me from RESN IR so I assume it's public domain)
Resonant’s Strategy to Tackle 5G
By Daniel Carlson -February 13, 2019
Trading up well over 100% in 2019, Resonant (RESN) is the best performing stock in Tailwinds’ Universe. However, this strength is more of a bounce of an extremely oversold condition. There remains significant upside in shares of RESN…if they can execute on their goal of disrupting the RF filter marketplace.
To date, we have been, and remain, very excited about the company’s ISN platform. They have developed a software product that enables faster and cheaper designs of filters. The original plan was that phone manufacturers would be large buyers of these filters. Why wouldn’t they be, right? The products save money and that being price competitive is the key to survival in electronics manufacturing.
The truth, however, was that there’s more to gaining market share than building a portfolio of me-too products. Resonant’s products are indeed everything they are advertised to be. The problem is that gaining customer traction as a small piece of the supply chain is harder and takes longer than anticipated.
When Resonant talks to customers, they have been facing headwinds. Their products compete against those from big companies like Broadcom and Murata. Customers switch from these companies very reluctantly as they have a proven track record of volume production of a qualified, reliable product.
At the same time, RESN designs are going head to head against internal design groups. When your buyer might have to lay off their team if they shift to your product, there will be a major internal discussion (battle?) before any shift is made.
All of which means that, to date, Resonant has delivered on products and design, yet failed to meet expectations with ramping royalty revenues as their customers transition to OEM sales. . Don’t get me wrong, they have been making continual progress and getting closer to an inflection point, but with a royalty-based business model, in the risk averse smartphone market this has been slow.
ISN Leads to Faster Designs
To be clear, this note is not meant as an attack against Resonant. They have delivered technically, which is the most important thing they can do. Yes, sales have been slower to materialize than expected…or guided to, for that matter. But, behind the scenes the progress has been substantial. In this regard, I’m referring to their revolutionary ISN platform.
The ISN product developed by Resonant is indeed industry changing. As a refresher, it enables RF filters to be designed primarily in software. Instead of drafting designs that need to be fabricated, tested, then reconfigured, refabricated, etc., ISN allows the bulk of the design work to take place in the software. The result of this is the ability to create designs much cheaper and faster than otherwise possible.
The other benefit of designing in software is the ability to try new designs and structures without needing a fab nor a significant budget. A radical new design can be tried in software to the level at which its future performance is well enough understood to give it the green light on fabrication. Thus, many possible changes to design and structure of a filter can be sampled theoretically before launching prototypes.
Which leads us to 5G. As someone said to me the other day, “If all you have is a hammer, everything looks like a nail.” Broadcom and others are taking existing filter designs and working diligently on improvements to get them to 5G. This is a long and slow process. And, it might never get there.
5G…A Game Changer?
You may have figured out where I’m going with this story by now. Little Resonant starts out trying to make existing products cheaper and faster, and finds validation of their designs in 4G in a very mature and competitive market. Then Resonant applies the power of its ISN tool to the nascent 5G market.
The next generation of cell phones will all be running on 5G networks. What this means is that much (much!) more data, in particular video, is going to be pushed out to phones. In order to have the bandwidth to support this, network operators are moving to spectrum with broad swaths of availability. This exists in the spectrum north of 3 GHz.
Future filters need to work over a larger bandwidth and also at much higher power. These are the two demands of 5G and the complexity of this shift is leading to many technological challenges. In the RF filter space, Resonant saw that current filter building blocks were going to have a tough time adapting to these new demands; if ever.
Which is the genesis of XBAR, Resonant’s answer to the 5G issue. XBAR is a 5G filter platform. It is also the first product in Resonant’s portfolio that is not simply a better version of an existing product. Instead, XBAR is a whole new structure for filters.
As such, XBAR represents a major tactical shift for Resonant. With XBAR Resonant hopes to be the first to market with a high performing 5G filter for cell phones. Sure, the other filter manufacturers have products, but, in initial testing, it appears the specs on XBAR could offer vastly better performance, particularly in regard to interference as 5G traffic inevitably picks up.
MWC…The Big Unveiling
Later this month, the wireless world will converge on Barcelona for the Mobile World Congress. This is where the first XBAR filters for 5G, currently being fabricated for the Congress, will be revealed.
How will this be received is the big question for investors. I believe there will be two reactions. The first is going to be great surprise and delight. The product being shown will be revolutionary. The structure is very different from the typical BAW structure. Mobile phone manufacturers should be very enthusiastic.
Unless, of course, you were around for the development of FBAR. The current standard in filters took 10 years to perfect. For those in that process, XBAR will look very premature. Except for one thing; ISN. With their design platform, the timeline to development of an acceptable XBAR product available for installation in phones should be degrees of magnitude shorter.
At Tailwinds, having dug deeper into XBAR and having gotten a much better understanding of the product, we are in the excited camp. This product is a game changer for RESN. Instead of fighting for market share in existing product lines, they are moving towards being a leader in the hottest area of wireless: 5G.
We believe RESN needs to be reevaluated based on XBAR. If the product is as successful as it appears it may be, this stock could truly become a 5G must own. There is work to be done, and a product to be proven, but the potential appears greater than ever.
News: MediPharm Labs Signs $35 Million Private Label Cannabis Oil Sale Agreement with Option for Additional $13.5 Million
TORONTO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSXV: LABS) (OTCQB: MLCPF) (“MediPharm”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that its wholly-owned subsidiary, MediPharm Labs Inc. (“MediPharm Labs” or the “Company”), has entered into a significant sales agreement with a leading Licensed Producer to supply approximately $35 million of private label purified cannabis oil concentrates. Under the terms of the agreement, the Licensed Producer will immediately purchase upfront $7.66 million of cannabis oil concentrate from MediPharm Labs’ inventory in February 2019. In addition, the Licensed Producer will purchase a minimum of $27 million of cannabis oil concentrate over a 12-month period commencing March 2019, with an option to purchase an additional $13.5 million over the same period, bringing the total potential aggregate value of the agreement to over $48 million to February 2020.
MediPharm Labs’ private label program is a high margin business for the Company, whereby it opportunistically procures dry cannabis flower and trim from its thirteen product supply partners, to produce proprietary cannabis oil concentrate products for resale globally on a private label basis. This is MediPharm Labs’ fourth private label sales agreement to date. In total, these four agreements have aggregate potential value of over $85 million in the 15-month period that commenced December 2018.
“As the cannabis industry continues to rapidly grow and evolve, MediPharm Labs has quickly established itself as a dominant player and leading provider of private label cannabis oil concentrates to other Licensed Producers and branded product manufacturers. We have also demonstrated the permanent need for a specialized extraction provider to fulfill and secure the cannabis supply chain for medical and recreational consumers,” said Pat McCutcheon, CEO of MediPharm Labs. “With our significant first mover advantage, deep expertise, leading-edge proprietary technology to manufacture and develop high-quality cannabis oil and concentrate products at commercial scale, we have quickly been able to execute several major contracts already and continue to see robust demand for our specialized products and services and are well positioned to achieve strong revenue growth as a dominant extraction company in the cannabis industry.”
As an agnostic supplier of pharmaceutical grade cannabis oil concentrates to the global cannabis industry, MediPharm Labs has demonstrated its ability to strengthen and further secure the domestic supply chain for high-demand cannabis oil. This new supply agreement, combined with a large, long-term oil supply agreement previously announced with Canopy Growth Corporation, represents less than 10% of MediPharm Labs’ annual extraction capacity of 150,000 Kg, which is currently being expanded to 250,000 Kg of annual extraction capacity, with completion expected Q2 2019.
To date, MediPharm Labs has completed four private label wholesale agreements for cannabis oil concentrate supply (including Canopy Growth Corporation); five long-term cannabis concentrate program (tolling) agreements with James E. Wagner Cultivation Corp., Emerald Health Therapeutics, Inc., INDIVA Limited, The Supreme Cannabis Company, Inc. and TerrAscend Corp. Additionally, the Company has completed bulk purchases and/or off-take agreements with thirteen Licensed Producers securing dried cannabis supply to build MediPharm’s oil inventories for private label sale. The Company also continues to make progress on new partnership agreements with additional Licensed Producers and branded product manufacturers for cannabis private label manufacturing, as well as partnerships to purchase cannabis concentrates for global export for private label and research and development.
The slow and painful drop is not surprising given their lack of commercial traction and no news on the trial front, but I def agree that the price now is very attractive given the potential. But as is often the case with small biotechs, their pipeline is only half of the success.. the management team is critical. Does the new(ish) CEO have the ability to turn them around? I hope so. I had a modest position from 2+ years ago that I never sold and is virtually worthless today. I may purchase some more soon.. kinda waiting for more positive signals.
Strong 120% rise since your post. Will the momentum continue, or sag before they can show royalty revenue?
Strong rebound off of recent lows. Was clearly oversold and a bargain. Still, we need to see meaningful royalty revenue start to ramp for this rally to be sustainable. I'm still long.
F'ing love that analogy! Well said.
100% agreed. They have never sold any drug to anyone ever before, and there is zero reason to be optimistic that this generic combo, despite its benefits, will sell itself. This was a desperate move by Kitov to get cash, as as mentioned in another post, it sounds like the amateurs at Coeptis are seeking to leverage this deal to raise their own funds. At this point, we're not even sure Coeptis will raise enough to start their business, and be able to pay the fees to Kitov.
I really agree here. Worst possible partner for the US, and no meat for shareholders for the next 12-15 months min. Warrants will surely expire worthless, and I expect the share price will drop significantly from here over the next months.
Just stumbled onto this co.. was doing some research. Great interim results in their Phase2b! Encouraging grants in the past, and prestigious medical centers for their trials. I may nibble to create a starting position here.
I can't find any webinars or conf call recordings that the company has given, do you know if any exist?
Fair enough - I didn't mean to imply 'guilt by association', I'm just trying to learn more and the more I learn the more I scratch my head. Mehalick seems to appear in quite a few SEC filings as a 'consultant' receiving shares for services in multiple OTC companies. That alone sets off many alarm bells for me.
This deal is far worse than I had feared a partnership agreement would be given the time that had passed since FDA approval. As you said, it makes no sense.
Coeptis Pharma CEO David Mehalick formerly founded World Health Alternatives. Is this the same company: https://archives.fbi.gov/archives/pittsburgh/press-releases/2012/world-health-alternatives-ceo-sentenced-to-more-than-10-years-in-prison-for-41-million-fraud-scheme
Coeptis website and team looks super amateur. This smells terrible. If Kitov believed their new combo drug had commercial appear they would never have signed a 15-year exclusive distrib agreement in the world's largest pharma market to an unknown 2 year old company whose CEO has so little pharma background.
It's pretty disappointing that they signed with a virtually unknown company with no track record, and made it an exclusive deal for 15 years. No mention of minimums. IMO there is little hope of meaningful US commercial traction with this partner.
Agree that warrants are a long-shot now, with first revenues to Kitov coming only in Q4 of 2019. There is still a chance they generate decent sales (+ abroad) but for the next 8-12 months this stock is dead.
Seeking Alpha article with perspective on RESN's recent drop: https://seekingalpha.com/article/4222849-resonant-oversold-misunderstood?dr=1
Didn't think this post would be relevant again, but here we are back at 2016 prices. Way, way oversold IMO. I picked up even more today. This seems to be like impatient investors bailing. The fact is that their execution has been fairly consistent since 2016, and they're in a very exciting space (5G proliferation / IOT is second only to Canabis for me these days).
Thanks yeah.. I just found it about 33 minutes in to to the call he mentions "5" as the lower bound, and that for a 2-3 year lock-in.
Can anyone clarify what the sale price per g/kg is for Pure SunFarms? I know they're expecting their product cost to be under $1 (lowest in the industry), and I've seen the per-gram prices listed for various states (which I guess is retail? Or is that wholesale?), but what is the sale price they are expecting? And is the price fixed for the JV with Emerald Health for 40% of their production? (I know, I could read the JV agreement..)
Just trying to get a realistic understanding of the impact to the bottom-line of VFF. I thought I also heard DiGiglio say "$2 per g" when referring to price/profit on the call yesterday, but I didn't catch the context.
Thank in advance. Loved DiGiglio's confidence again yesterday.
Per yesterday's earnings call:
* shelf S3 for funds should they need any
* project to be at quarterly revenue of $1MM by mid 2019
* revenue for Q4 this year (typically a big Q for handset shipments) expected to be midway between Q3's revenue and the that $1MM point
* currently 60 "devices contracted", expect to be at 75 by EOY
* $270MM filter value at YE 2017, expect $600MM this year
Overall the story still sounds good, but up-take is definitely slower that they'd anticipated (they'd originally projected $1MM quarterly revenue by now, so they're tracking 6mos late).
They have high hopes for XBAR as 5G adoption picks but (but we have no proof yet that this will be a commercial success at all).
I picked up a little more AH last night as it plummeted well below what I think is reasonable for a long-term hold. I think overall the company is still in an amazing space with IP and products that are market leading, so I'm still long on RESN, esp at these depressed prices.
Yeah, that was not only painful, but outright disingenuous toward shareholders. I held through that and am happy to see it's mostly recovered now. They will indeed need to raise more funds, but they're about as close to turning the corner as they can be. And IMO the share price doesn't price in success in even one of their candidate drugs. RDHL is also one of my largest holdings today.
This screams BUY. 3 phase 3's, all with good prelim readouts, and all 3 blockbusters. But I'm biased as I've been a RDHL shareholder for a couple of years now. 2019-2021 will be amazing for this stock IMO.
Stock price down 75% since that post.. and the company has advanced considerably on both their Reservatrol and Stevia programs. With their Cargill JV, Eversweet should start to see sales ramp this Q and in 2019. With Reservatrol, very encouraging findings from the prelim results of a 2 year study (see below) and with Nootkatone a potential deal with the US CDC (and with EPA approval imminent?!).
Reservatrol Study results at 1 year:
"Preliminary results provided from an interim evaluation after 12 months (halfway) in the trial revealed significant benefits of RES vs placebo. Headline results included that RES reduced the loss of bone mineral density in the neck of the femur resulting in a 12% improvement in the FRAX t-score, a 36% reduction in hip fracture risk and a 9% reduction in the 10 year risk of a major osteoporotic fracture."
The core tech of this company is to synthesize natural compounds in yeast, but on an industrial scale, producing exact replicas of the natural compounds but with lower cost and higher purity. From what I can tell, their yeast-based process is one of the most advanced in the world, and has some decent IP to protect it.
Applications today cover reservatrol, nootkatone, stevia extracts, vanillin, and valencene, but the approach would seem to be applicable to many many other natural compounds (I'm thinking canabinoids).
I am taking a long position in Evola this week.
Just to compare today with last June (16 months ago):
filter design value under license today: $475MM (up from $290MM)
number of clients: 10 (up from 8)
cash on hand: $31MM (up from $18MM)
Decent progress, in other words, despite little news and eroding share price lately.
I remain optimistic, and may pick up more shares after hearing their next update, if the price stays this low.
Some news out the other day, but hard to estimate its impact. XBAR is being called a "new filter technology" and a "resonator" but not an actual "RF Filter". Is this an actual manufactured chip as opposed to a design approach? If so, will RESN seek to manufacture and re-sell them, or license their manufacture to customers? If not, will RESN seek to license this design approach for third-party use or can it be only used in designs RESN is commissioned to produce?
In any case, for now it's merely a simulation (though they have an excellent track record of accurate simulations).
I guess we'll find out a little more on Oct 23. A staggering drop in share price lately, and no new announcements of design wins, or tear-downs revealing in which handsets their chips are being used.
Next shareholder update could be ugly if we don't see royalty revenue up significantly.
---
Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for wireless devices, today announced its breakthrough 5G filter technology – XBAR – will be introduced for the first time at the 2018 IEEE International Ultrasonics Symposium (IUS), to be held October 22-25, 2018, in Kobe, Japan.
The new breakthrough is a fundamentally novel resonator, the building block of an RF filter. The technology is important because it is designed to offer a cost-effective filter operating at frequencies of 3GHz and higher, making it the first filter technology designed from the beginning for 5G.
“The high bandwidth 5G data services will operate at frequencies of 3.5GHz – 6GHz and higher, but today’s best filter technologies have limitations operating at these frequencies,” said George B. Holmes, CEO of Resonant. “The early results from our XBAR initiative are very promising and we are working hard to provide a cost-effective, high-performance option for 5G services.”
Using its ISN technology, Resonant has developed this new structure, which in simulations outperforms best-in-class FBAR resonators. The company filed patent applications on the technology earlier this year.
More details of the technology will be made available at IUS and in a press release that will be issued on October 23, 2018.
Wish I had a stop loss on this one, I stopped watching and had been up considerably. Wonder what's going on? Still bullish long term, but don't like the color red on my position too much.
The JV already has the "option" for those other areas, so IMO as soon as the entire model starts to prove itself out (grow, harvest and sales), they will pull the trigger on the rest. I don't expect them to do it sooner.
For those who may not know this (mostly those south of the border), the LCBO is one of the largest importer and distributor of alcoholic beverages in the entire world -- due to the province of Ontario being Canada's most populous and since it's the only entity licensed to deal with alcohol. So the supply chain and wholesale experience that Mr. Dosanjh should not be understated. IMO it's a major hire and should help PureSun ramp up nicely in the coming months and years.
MTP clearly on nobody's radar, but some very encouraging news on their first in-human trials today that bodes well for the rest of their pipeline. Share price is near an all-time low. I am buying more today (price has settled since the morning pop), with a plan to hold very long.
Huge day for Midatech. 500x normal daily volume for the ADRs in the US, and closed up 75%. Went as high as 175% during intraday trading.
Still long. Bought a bit more in Dec.
Up 20% today on huge volume, but no news. Simply institutionals finally buying in?
https://midwaymonitor.com/institutional-investors-have-increased-interest-in-resonant-inc-nasdaqresn/367061/
"According to the SEC’s latest filings, institutions owning shares of Resonant Inc. (NASDAQ:RESN) have increased their transactions by 6.82%. Institutions now own 11.90% of the company."